Location: China, Shanghai
Employees: 11-50
Total raised: $68M
Founded date: 2021
Investors 1
| Date | Name | Website |
| - | LAV | lavfund.co... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 19.07.2024 | Series A | $35M | - |
| 07.04.2022 | Series A | $33M | - |
Mentions in press and media 17
| Date | Title | Description |
| 10.11.2025 | Rona Therapeutics Presents Phase 1 Data for RN0361, a Long-Acting APOC3-Targeting siRNA, at the American Heart Association 2025 Scientific Sessions | NEW ORLEANS, Nov. 10, 2025 /PRNewswire/ -- Rona Therapeutics, a global leader in developing next-generation RNAi therapeutics, presented highlights of Phase 1 clinical data for RN0361, a long-acting Apolipoprotein C3 (ApoC3) siRNA. RN0361 a... |
| 15.09.2025 | Rona Therapeutics Announces IND Filing of RN3161, a Highly Potent and Durable INHBE siRNA for Obesity | SHANGHAI and SANTA BARBARA, Calif., Sept. 15, 2025 /PRNewswire/ -- Rona Therapeutics, a global leader in developing next-generation RNAi therapeutics, announced today the successful submission of RN3161 to the Australian Human Research Ethi... |
| 29.05.2025 | Rona Therapeutics Announces Breakthrough Data on Potential Annual Dosing RNAi Therapy RN026 Targeting Lipoprotein(a) in The National Lipid Association (NLA) Scientific Sessions 2025 | SHANGHAI, May 29, 2025 /PRNewswire/ -- Rona Therapeutics, a global leading RNA therapy company, today announced preclinical data for its self-developed RNA interference (RNAi) therapy RN026 at the National Lipid Association (NLA) Annual Sci... |
| 21.04.2025 | Rona Therapeutics Announces NMPA Approval of IND Application for RN1871, a Novel Angiotensinogen (AGT)-Targeting siRNA Drug for Hypertension | SHANGHAI, April 21, 2025 /PRNewswire/ -- Rona Therapeutics, a biotechnology company pioneering innovative RNA-targeted therapies, announced that the Investigational New Drug (IND) application for RN1871, a small interfering RNA (siRNA) drug... |
| 18.11.2024 | Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions | Single dose of RN0191 achieved up to 95% individual maximum and 87% mean maximum PCSK9 reduction, and up to 74% individual maximum and 56% mean maximal LDL-C lowering Robust and sustainable treatment effects support at least bi-annual dosin... |
| 25.07.2024 | Rona Therapeutics Secures $35 Million to Propel RNA Innovations** ** | ** In the fast-paced world of biotechnology, funding is the lifeblood that fuels innovation. Rona Therapeutics, a clinical-stage company based in Shanghai, has just secured a significant $35 million in Series A+ financing. This funding roun... |
| 19.07.2024 | Rona Therapeutics: Nucleic Acid Drug R&D Company Raises $35 Million | Rona Therapeutics, a clinical stage pioneering platform company in nucleic acid drug research and development, today announced it raised $35 million in Series A+ funding. This funding round was led by LongRiver Investments, with participati... |
| 19.07.2024 | Rona Therapeutics Raises $35 Million Series A+ Financing to Advance Innovative Metabolic siRNA Pipeline in Clinic and Next Generation RNA Platforms | Financing led by LongRiver Investments with participation by new and existing global investment funds Rona will use proceeds to progress leading metabolic siRNA pipeline programs into global development and expand extra-hepatic delivery pla... |
| 19.07.2024 | Rona Therapeutics Raises $35M Series A+ Financing | Rona Therapeutics, a Shanghai, China-based clinical stage platform company which specializes in nucleic acid drug research and development, raised $35M in Series A+ funding. The round was led by LongRiver Investments with participation from... |
| 19.07.2024 | Rona Therapeutics Raises $35 Million Series A+ Financing to Advance Innovative Metabolic siRNA Pipeline in Clinic and Next Generation RNA Platforms | Financing led by LongRiver Investments with participation by new and existing global investment funds Rona will use proceeds to progress leading metabolic siRNA pipeline programs into global development and expand extra-hepatic delivery pla... |
Show more